Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASM0015
- Development stage
- Preclinical
- Lead developer
- Amtix Bio
- Modality
- Small Molecules
01
Overview
ASM0015 (also known as ASM-0015) is a preclinical-stage small molecule antibacterial therapeutic being developed by Amtix Bio in collaboration with Seoul National University. The drug is designed to target multidrug-resistant Gram-negative bacterial infections, with a specific focus on Carbapenem-resistant *Acinetobacter baumannii* (CRAB), a high-priority pathogen identified by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). ASM0015 is being developed under a South Korean government-funded research and development project (2023–2024) aimed at addressing the critical global challenge of refractory multidrug-resistant bacterial infections.
Beyond the preview
Go deeper on ASM0015.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASM0015.